Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma

Journal of Periodontology

Volumn 77, Issue 3, 2006, Pages 523-533

  Kalpidis, Christos D R ^a,c   Lysitsa, Stella N ^b   Lombardi, Tommaso ^b   Kolokotronis, Alexandros E ^a   Antoniades, Demetrios Z ^a   Samson, Jacky ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Periodontal Health Center   (Greece)

Author keywords

Acquired immunodeficiency syndrome; Gingiva pathology; Gingival diseases; Gingival neoplasms; Human herpesvirus 8; Kaposi sarcoma

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BISEXUALITY; CASE STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; GINGIVA DISEASE; GINGIVA TUMOR; GINGIVAL BIOPSY; GREECE; HISTOPATHOLOGY; HOMOSEXUALITY; HUMAN; HUMAN HERPESVIRUS 8; INCIDENCE; KAPOSI SARCOMA; MALE; MEDICAL RECORD REVIEW; MOUTH LESION; PIGMENTATION; REVIEW; SWITZERLAND; AFRICA; AIDS RELATED COMPLEX; ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; JAW TUMOR; MIDDLE AGED; MOUTH MUCOSA; PATHOLOGY; RETROSPECTIVE STUDY; UNITED STATES; VIROLOGY;

ADULT; AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GINGIVAL NEOPLASMS; HERPESVIRUS 8, HUMAN; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; PALATAL NEOPLASMS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; UNITED STATES;

EID: 33646379629     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2006.050226     Document Type: Review

References (82)

1. Jaffe HW, Bregman DJ, Selik RM. Acquired immune deficiency syndrome in the United States: The first 1,000 cases. J Infect Dis 1983;148:339-345.
2. Biggar RJ, Horm J, Fraumeni JF Jr., Greene MH, Goedert JJ. Incidence of Kaposi's sarcoma and mycosis fungoides in the United States including Puerto Rico, 1973-81. J Natl Cancer Inst 1984;73:89-94.
3. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 1990;335:123-128.
4. Epstein JB, Scully C. HIV infection: Clinical features and treatment of thirty-three homosexual men with Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol 1991;71:38-41.
5. Ficarra G, Berson AM, Silverman S Jr., et al. Kaposi's sarcoma of the oral cavity: A study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. Oral Surg Oral Med Oral Pathol 1988;66:543-550.
6. Gorsky M, Epstein JB. A case series of acquired immunodeficiency syndrome patients with initial neoplastic diagnoses of intraoral Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:612-617.
7. Reichart PA, Langford-Kuntz A, Pohle HD. Epidemic oro-facial Kaposi's sarcoma (eKS) - Report on 124 cases. Eur J Cancer B Oral Oncol 1993;295:187-189.
8. Flaitz CM, Jin YT, Hicks MJ, Nickhols CM, Wang YW, Su IJ. Kaposi's sarcoma-associated herpesvirus-like DNA sequences (KSHV/HHV-8) in oral AIDS-Kaposi's sarcoma: A PCR and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:259-264.
9. Aguirre JM, Echebarria MA, Ocina E, Rocaboda L, Montejo M. Reduction in HIV-associated oral lesions after highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88: 114-115.
10. Greenspan D, Canhola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001;357: 1411-1412.
11. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002;8(Suppl. 2):34-39.
12. Greenwood I, Zakrzewska JM, Robinson PG. Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over 7 years. Oral Dis 2002;8(Suppl. 2): 90-94.
13. Patton LL, McKaig R, Strauss R, Roggers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304.
14. Regezi JA, Jordan RCK. Oral Kaposi's sarcoma: Biopsy accessions as an indication of declining incidence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:399.
15. Greenspan D, Greenspan JS. Oral mucosal manifestations of AIDS. Dermatol Clin 1987;5:733-737.
16. Narani N, Epstein JB. Classification of oral lesions in HIV infection. J Clin Periodontol 2001;28:137-145.
17. Langford A. Gingival and periodontal alterations associated with infection with human immunodeficiency virus. Quintessence Int 1994;25:375-387.
18. Terezhalmy GT, Riley CK, Moore WS. Kaposi's sarcoma. Quintessence Int 2000;31:284-285.
19. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1993;41:1-5.
20. Lumerman H, Freedman PD, Kerpel SM, Phelan JA. Oral Kaposi's sarcoma: A clinicopathologic study of 23 homosexual and bisexual men from the New York metropolitan area. Oral Surg Oral Med Oral Pathol 1988;65:711-716.
21. Lausten LL, Ferguson BL, Barker BF, Cobb CM. Oral Kaposi sarcoma associated with severe alveolar bone loss: Case report and review of the literature. J Periodontol 2003;74:1668-1675.
22. Langford A, Pohle HD, Reichart P. Primary intraosseous AIDS-associated Kaposi's sarcoma. Report of two cases with initial jaw involvement. Int Oral Maxillofac Surg 1991;20:366-368.
23. Nichols CM, Flaitz CM, Hicks MJ. Primary intraosseous Kaposi's sarcoma of the maxilla in human immunodeficiency virus infection. Review of literature and report of case. J Oral Maxillofac Surg 1995;53: 325-329.
24. Regezi JA, MacPhail LA, Daniels TE, et al. Oral Kaposi's sarcoma: A 10-year retrospective histopathologic study. J Oral Pathol Med 1993;22:292-297.
25. Green TL, Beckstead JH, Lozada-Nur F, Silverman S Jr., Hansen LS. Histopathologic spectrum of oral Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol 1984;58:306-314.
26. Petit JC, Ripamonti U, Hille J. Progressive changes of Kaposi's sarcoma of the gingiva and palate. Case report in an AIDS patient. J Periodontol 1986;57: 159-163.
27. Daly CG, Allan BP, Bhagwandeen SB, Sutherland DC. Kaposi's sarcoma of the palate in a patient with AIDS: An unusual presentation. Aust Dent J 1989;34: 101-105.
28. Reichart PA, Schiødt M. Non-pigmented oral Kaposi's sarcoma (AIDS). Report of two cases. Int J Oral Maxillofac Surg 1989;18:197-199.
29. Wescott WB, Werksman L. Kaposi's sarcoma in patients with AIDS. J Am Dent Assoc 1989;119(Suppl.): 37-39.
30. Blumenfeld W, Egbert BM, Sagebiel RW. Differential diagnosis of Kaposi's sarcoma. Arch Pathol Lab Med 1985;109:123-127.
31. Barrett AP, Bilous AM, Buckley DJ, Kefford RF, Packham DR. Clinicopathological presentations of oral Kaposi's sarcoma in AIDS. Aust Dent J 1988;33: 395-399.
32. Reis-Filho JS, Souto-Moura C, Lopes JM. Classic Kaposi's sarcoma of the tongue: Case report with emphasis on the differential diagnosis. J Oral Maxillofac Surg 2002;60:951-954.
33. Shiboski CH, Winkler JR. Gingival Kaposi's sarcoma and periodontitis. A case report and suggested treatment approach to the combined lesions. Oral Surg Oral Med Oral Pathol 1993;76:49-53.
34. Bezold G, Messer G, Peter RU, Flaig MJ, Sander CA. Quantitation of human herpes virus 8 DNA in paraffin-embedded biopsy of HIV-associated and classical Kaposi's sarcoma by PCR. J Cutan Pathol 2001;28: 127-130.
35. Boshoff C, Schultz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpes virus infects endothelial and spindle cells. Nat Med 1995;1:1274-1278.
36. Kennedy MM, Lucas SB, Jones RR, et al. HHV-8 and Kaposi's sarcoma: A time cohort study. Mol Pathol 1997;50:96-100.
37. Nuovo M, Nuovo G. Utility of HHV8 RNA detection for differentiating Kaposi's sarcoma from its mimics. J Cutan Pathol 2001;28:248-255.
38. Ryan P, Aarons S, Murray D, et al. Human herpesvirus 8 (HHV-8) detected in two patients with Kaposi's sarcoma-like pyogenic granuloma. J Clin Pathol 2002; 55:619-622.
39. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 2001;15: 439-449.
40. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338:948-954.
41. Renwick N, Halaby I, Weverling GJ, et al. Serocon-version for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998;12: 2481-2488.
42. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94: 1204-1210.
43. Cattelan AM, Calabro ML, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: Biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001;28:44-49.
44. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000;14:987-993.
45. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000; 27:390-401.
46. Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst Monogr 2001;28:1-4.
47. Bassett MT, Chokunonga E, Mauchaza B, Levy L, Ferlay J, Parkin DM. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer 1995; 63:29-36.
48. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: Maturation of the epidemic in Uganda. AIDS 1999;13:2563-2570.
49. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 2000;82: 1585-1592.
50. Chitsike I, Siziya S. Seroprevalence of human immunodeficiency virus type 1 infection in childhood malignancy in Zimbabwe. Cent Afr J Med 1998;44: 242-245.
51. Chidzonga MM. HIV/AIDS orofacial lesions in 156 Zimbabwean patients at referral oral and maxillofacial surgical clinics. Oral Dis 2003;9:317-322.
52. Lager I, Altini M, Coleman H, Ali H. Oral Kaposi's sarcoma: A clinicopathologic study from South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:701-710.
53. Arendorf TM, Bredekamp B, Cloete C, Wood R, O'Keefe E. Intergroup comparisons of oral lesions in HIV-positive South Africans. Oral Dis 1997;3(Suppl. 1):54-57.
54. Tukutuku K, Muyembe-Tamfum L, Kayembe K, Odio W, Kandi K, Ntumba M. Oral manifestations of AIDS in a heterosexual population in a Zaire hospital. J Oral Pathol Med 1990;19:232-234.
55. Ranganathan K, Reddy BVR, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 south-Indian patients. Oral Dis 2000;6:152-157.
56. Khongkunthian P, Grote M, Isaratanan W, Piyaworawong S, Reichart PA. Oral manifestations in HIV-positive adults from northern Thailand. J Oral Pathol Med 2001;30:220-223.
57. Holmes HK, Stephen LXG. Oral lesions of HIV infection in developing countries. Oral Dis 2002;8(Suppl. 2): 40-43.
58. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes virus-like DNA sequences in AIDS-associated Kaposis sarcoma patients. Science 1994;266: 1865-1869.
59. Blauvelt A. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Adv Dermatol 1999;14:167-206.
60. Hille JJ, Webster-Cyriaque J, Palefski JM, Raab-Traub N. Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Dis 2002;8(Suppl. 2):161-168.
61. Cannon MJ, Laney AC, Pellett PE. Human herpesvirus 8: Current issues. Clin Infect Dis 2003;37:82-87.
62. Dezube BJ. New therapies for the treatment of AIDS-related Kaposi sarcoma. Curr Opin Oncol 2000;12: 445-449.
63. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002;15: 310-326.
64. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 1999;93:4031-4033.
65. Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 2003;17:747-762.
66. Mitsuyasu RT. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol 2000;12: 174-180.
67. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002;2:281-292.
68. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15:629-633.
69. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-1830.
70. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:270-274.
71. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV Cohort Study. BMJ 1999;319:23-24.
72. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002;98:916-922.
73. Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32:2711-2720.
74. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumor growth. Lancet Oncol 2003;4:537-547.
75. Piedbois P, Frikha H, Martin L, Levy E, Haddad E, Le Bourgeois JP. Radiotherapy in the management of epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1994;30:1207-1211.
76. Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: A retrospective study of 643 cases. Radiother Oncol 1998;46:19-22.
77. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Eur J Cancer B Oral Oncol 1995;31B:280-285.
78. McCormick SU. Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: Report of 10 patients with 2-year follow-up. J Oral Maxillofac Surg 1996;54:583-587.
79. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002;38:460-467.
80. Lucatorto FM, Sapp JP. Treatment of oral Kaposi's sarcoma with a sclerosing agent in AIDS patients. A preliminary study. Oral Surg Oral Med Oral Pathol 1993;75:192-198.
81. Sulis E, Floris C, Sulis ML, et al. Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma. Eur J Cancer Clin Oncol 1989;25: 759-761.
82. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M. Intralesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 1993; 28:966-972.